Piramal Pharma Limited

AI Analysis

The pharma sector in India is driven by domestic demand, export opportunities (especially to regulated markets), and R&D capabilities. Piramal Pharma's global presence and CDMO business are key aspects.

Trading Insight

Evaluate Piramal Pharma based on its segment-wise growth prospects, margin profiles, and competitive landscape within the CDMO and consumer healthcare space.

Quick check: PPLPHARMA bearish bias (-5.0% 1d), PEL neutral.

Key Evidence

•Piramal Pharma Limited acts as a Contract Development and manufacturing organization (CDMO)
•15 Manufacturing Sites across North America, the United Kingdom, and India.
•FY22 Revenue - 6701 Cr. → 10 Yr. CAGR: 13%.
•Demerged from Piramal Enterprise Ltd and was listed on BSE and NSE on 19th October 2022.
•Risk flag: Regulatory changes in key markets

Affected Stocks

PPLPHARMAPiramal Pharma Limited

Mixed

The article provides a factual overview of the company without new positive or negative developments.

PELPiramal Enterprises Ltd

Mixed

Mentioned as the parent company from which Piramal Pharma was demerged; no new impact on PEL.

Sectors:pharma

AI-powered analysis by

Anadi Algo News